tazocin 4 g/0,5 g prašak za otopinu za infuziju
pfizer croatia d.o.o., slavonska avenija 6, zagreb - piperacillinum, tazobactamum - prašak za otopinu za infuziju - 4 g + 0,5 g - urbroj: jedna bočica sadrži 4 g piperacilina u obliku piperacilinnatrija i 0,5 g tazobaktama u obliku tazobaktamnatrija
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
tygacil 50 mg/1 viala prašak za otopinu za infuziju
pfizer bh d.o.o. - tigeciklin - prašak za otopinu za infuziju - 50 mg/1 viala - 1 bočica sa praškom za otopinu za infuziju sadrži: 50 mg tigeciklin
benefix 250 i.j./1 bočica prašak i otapalo za otopinu za injekciju
pfizer bh d.o.o. sarajevo - nonakog alfa - prašak i otapalo za otopinu za injekciju - 250 i.j./1 bočica - 1 bočica sa praškom sadrži: 250 iu nonakog alfa (rekombinantni koagulacijski faktor ix)
benefix 500 i.j./1 bočica prašak i otapalo za otopinu za injekciju
pfizer bh d.o.o. sarajevo - nonakog alfa - prašak i otapalo za otopinu za injekciju - 500 i.j./1 bočica - 1 bočica sa praškom sadrži: 500 iu nonakog alfa (rekombinantni koagulacijski faktor ix)
benefix 1000 i.j./1 bočica prašak i otapalo za otopinu za injekciju
pfizer bh d.o.o. sarajevo - nonakog alfa - prašak i otapalo za otopinu za injekciju - 1000 i.j./1 bočica - 1 bočica sa praškom sadrži: 1000 iu nonakog alfa (rekombinantni koagulacijski faktor ix)
refacto af 250 i.j./1 bočica prašak i rastvarač za rastvor za injekciju
pfizer bh d.o.o. sarajevo - moroktokog alfa - prašak i rastvarač za rastvor za injekciju - 250 i.j./1 bočica - 1 bočica sa praškom sadrži: 250 iu moroktokog alfa (rekombinantni koagulacijski faktor viii)